NCT05744739 2025-10-21
Tomivosertib in Relapsed or Refractory Acute Myeloid Leukemia (AML)
Northwestern University
Phase 1 Active not recruiting
Clinical Trials
9 trialsNCT03690141 2024-06-21
An Open-label Study of the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer
Effector Therapeutics
Phase 2 Terminated
NCT04622007 2024-04-30
KICKSTART
Effector Therapeutics
Phase 2 Active not recruiting
NCT03616834 2023-03-22
Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy
Effector Therapeutics
Phase 2 Completed
NCT04261218 2022-07-20
Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of Tomivosertib Combined With Paclitaxel in Advanced Breast Cancer
Translational Research in Oncology
Phase 1 Completed
NCT02605083 2020-11-02
A Dose Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Advanced Solid Tumors
Effector Therapeutics
Phase 1/2 Terminated
NCT02937675 2020-11-02
A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral Tomivosertib (eFT-508) in Subjects With Hematological Malignancies
Effector Therapeutics
Phase 1/2 Terminated
NCT03258398 2019-07-18
A Study to Evaluate eFT508 Alone and in Combination With Avelumab in Subjects With MSS Colorectal Cancer
Effector Therapeutics
Phase 2 Completed
NCT03318562 2019-07-18
A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC
Effector Therapeutics
Phase 2 Terminated